In the face of rising multidrug-resistant (MDR) Gram-negative infections, traditional β-lactam/β-lactamase inhibitor (BL/BLI) combinations like piperacillin-tazobactam are increasingly ineffective. Enter the new-generation BL/BLI agents — designed to overcome resistance, especially from carbapenemase-producing organisms.
 
Whether you’re preparing for the FRCPath Medical Microbiology Part 2 exam, reviewing antimicrobial policies, or guiding therapy in a real-time MDT, understanding these agents is essential.